by Dr. C.H. Weaver M.D. updated 12/2018
About Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) starts in immune cells called B-cells. It is the most common adult leukemia with over 15,000 individuals diagnosed annually in the United States and almost 5,000 patients succumb to the condition. CLL is not a rapidly growing cancer, but the cancerous cells accumulate in blood, bone marrow, lymph nodes and spleen, resulting in enlargement of these organs and decreased bone marrow blood cell production and immune function. CLL interferes with the normal production of antibodies and immunoglobulins, so the body cannot properly fight infections.
Although CLL may respond to therapy, it is currently considered an incurable disease, as most patients will experience a return of their cancer. There are several different treatment options available for CLL, and researchers continue to evaluate the effectiveness of these different treatment strategies to determine optimal therapeutic approaches for each patient.
The BCL-2 protein is a type of protein that contributes to CLL cell’s survival. Overexpression of the BCL-2 protein in CLL cells is associated with increased survival time of the leukemia cells as well as resistance to standard chemotherapy. Venclexta is an agent that binds to the BCL-2 protein, thereby disabling its ability to keep cancer cells alive.
The FDA has approved Venclexta for the treatment of adults with CLL and small lymphocytic lymphoma (SLL), including those who have not received previous treatment.
Venclexta in Previously Untreated CLL
Investigators reported the results of a clinical trial comparing Venclexta plus Gazyva (obinutuzumab) with chlorambucil plus Gazyva in previously untreated CLL and coexisting medical conditions at the June 2019 American Society of Oncology Annual Meeting. 432 CLL patients with an average age of 72 years, were treated with either 12 months of Venclexta and six months of Gazya or six months of Gazyva and 12 months of chlorambucil and directly compared.
Overall 84.7 % in the Venclexta group responded to treatment compared with 71.3% in the chlorambucil- Gazya group and twice as many Venclexta treated patients experienced a complete remission.
After a median follow-up period of only 28.1 months there was evidence that the Venclexta combination significantly delayed CCL progression and prolonged survival compared to chlorambucil plus Gazyva. 88% of Venclexta treated patients survived without progression of their leukemia compared to only 64% of those treated with chlorambucil–Gazyva.
The most common side effects in Venclexta treated patients were low blood counts (neutropenia, thrombocytopenia, anemia), diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue and edema. The Venclexta labeling also includes a contraindication on the use of strong CYP3A inhibitors during initiation and ramp up of Venclexta therapy for CLL/SLL.
Venclexta for Recurrent CLL
Venclexta + Imbruvica
According to study results were published in the May 2019 online issue of the New England Journal of Medicine the combination of Imbruvica (Ibrutinib) and Venclexta (venetoclax), are very effective treatment when given together for high-risk and older patients with chronic lymphocytic leukemia (CLL).
Researchers from MDACC in Houston TX treated 80 previously untreated elderly or high risk CLL patients with the combination. Patients were an average age of 65 years with 30 percent over age 70, and 93% had high-risk genetic abnormalities.
Overall the combination therapy was well tolerated, and no additional side effects were reported, other those known to occur from the individual drugs. A total of 88% of patients experienced a complete remission following Venclexta + Imbruvica with normal or incomplete blood count recovery after 12 cycles of treatment. Sixty-one percent of patients had complete remission with undetectable minimal residual disease.
The current median follow-up of the trial is only 14.8 months so longer follow-up is needed to adequately assess the long-ultimate safety and effectiveness of the combination.(2)
Venclextx + Rituxan
A combination of Venclexta plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has recurred following prior therapies.(3,4d)
The MURANO clinical trial which directly compared two different treatment regimens in patients with CLL that had recurred following prior therapies. Overall 389 patients with CLL who were divided into two groups and treated with a standard treatment consisting of Treanda plus Rituxan, or Venclexta plus Rituxan.
Venclexta was already approved by the United States Food and Drug Administration (FDA) for the treatment of recurrent CLL with a 17 p deletion. However, its approval was based on results that measured anti-cancer responses, and the FDA has required follow-up data to include duration of responses and survival rates.
The results of the MURANO trial reported at a median follow-up time of nearly 36 months after the initiation of treatment demonstrated that the combination of Venclexta+Rituxan represented a “profound improvement” compared to the standard Treanda+Rituxan treatment.
- Updated 3 year overall survival rates are 88% among the group of patients treated with Venclexta + Rituxan compared with only 79% of those treated with Treanda+Rituxan.
- Survival without cancer progression is 71.4% for patients treated with Venclexta compared with 15.2 percent for those treated with Treanda+Rituxan.
- The Venclexta + Rituxan combination was generally well tolerated.a + Rituxan compared to Treanda+Rituxan.
- The Venclexta + Rituxan combination was generally well tolerated.
- The researchers concluded longer follow-up of data from the MURANO trial will continue to help determine the true effectiveness of Venclexta + Rituxan combination therapy for CLL patients.
- The New England Journal of Medicine (2019; June 4. DOI:10.1056/NEJMoa1815281)
- Seymour J, Kipps T, Eichhorst B, et al. Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia – results from pre-planned interim analysis of the randomized phase 3 Murano study. 59th annual meeting of the American Society of Hematology. Late-breaking abstract #2. Available at: https://ash.confex.com/ash/2017/webprogram/Paper109076.html. Accessed February 26, 2018.
- Seymour J, et al. MURANO trial establishes feasibility of time-limited venetoclax-rituximab (VenR) combination therapy in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Presented at the 2018 American Society of Hematology Annual Meeting & Exposition: December 1, 2018; San Diego.
Copyright © 2018 CancerConnect. All Rights Reserved.